Literature DB >> 2276828

Piperacillin and netilmicin combination therapy for febrile episodes in neutropenic patients.

R Herbrecht1, J C Damonte, J P Bergerat, F Jehl, K L Liu, G Prevost, P Dufour, B Duclos, F Oberling.   

Abstract

We assessed the efficacy of a piperacillin (3 x 4 g/d) and netilmicin (5 mg/kg/d) combination therapy for infections in febrile neutropenic patients. The study was conducted over a 30-month period and 203 patients were included. Bone marrow transplant recipients were not included in this study. Origin of infection was documented in 101 (50%) episodes: 33 fungal, viral or parasitic infections and 68 bacterial infections mainly composed of septicemia. Of the 169 evaluable patients with proved bacterial infections or non-documented infections, 129 (76%) recovered with the piperacillin and netilmicin combination treatment. All gram-positive bacterial infections failing first line therapy were cured after the addition of vancomycin. Piperacillin and netilmicin appeared very effective in this large monocentric prospective study. It does not seem necessary to include vancomycin in first line therapy of infections of the neutropenic patients in our institution; however, vancomycin must be added early in the case of suspected or documented staphylococcal infection failing empiric treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276828     DOI: 10.1007/bf01647017

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients.

Authors:  S Lemerle; F de La Rocque; R Lamy; A Fremaux; F Bernaudin; J B Lobut; P Reinert
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

2.  [Treatment of infectious outbreaks in neutropenic patients with a piperacillin and amikacin combination].

Authors:  F Calvo; H de Castro; P Brice
Journal:  Presse Med       Date:  1986-12-20       Impact factor: 1.228

3.  A randomized trial of Timentin and tobramycin versus piperacillin and tobramycin in febrile neutropenic patients.

Authors:  M J Mackie; J T Reilly; S Purohit; C A Bartzokas
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

4.  Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients.

Authors:  R Gucalp; S Lia; J C McKitrick; P H Wiernik
Journal:  Am J Med       Date:  1988-07-25       Impact factor: 4.965

5.  A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients.

Authors:  R Sage; I Hann; H G Prentice; S Devereux; R Corringham; A V Hoffbrand; H Blacklock; L Stirling; M Guimaraes; E Trikka
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

6.  A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.

Authors:  P A Pizzo; J W Hathorn; J Hiemenz; M Browne; J Commers; D Cotton; J Gress; D Longo; D Marshall; J McKnight
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

7.  Piperacillin plus amikacin versus cefotaxime plus amikacin in neutropenic and feverish patients with malignant hemopathies.

Authors:  V Pavone; G Specchia; A Guarini; M Coniglio; L Iaculli; F Girardi; A Colucci; V Liso
Journal:  Chemioterapia       Date:  1988-10

8.  A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients.

Authors:  G M Smith; M J Leyland; I D Farrell; A M Geddes
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

9.  [Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin].

Authors:  J P Brion; J P Bru; M Michallet; B Corron; J Fauconnier
Journal:  Presse Med       Date:  1988-10-26       Impact factor: 1.228

10.  [Ceftazidime for the treatment of infections in neutropenic children].

Authors:  G Leverger; G Arlet; A Bancillon; G Schaison
Journal:  Presse Med       Date:  1988-10-26       Impact factor: 1.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.